logo
  

SyneuRx: Pentarlandir Shows Potential To Treat COVID, Prevent Inflammatory Syndrome In Phase 2 Trial

SyneuRx International's pentarlandir or SNB01 showed potential to treat COVID and/or prevent multisystem inflammatory syndrome, a very serious condition associated with the COVID-19, as per a phase 2 clinical trial results.

The trial evaluated the efficacy and safety of SNB01 (Pentarlandir), a novel COVID-19 oral antiviral candidate. Eighty-nine participants suffering from breakthrough or unvaccinated cases of COVID-19 were randomized evenly into high-dose, low-dose, and placebo groups, the company said in a statement.

The phase 2 study showed that Pentarlandir can reduce the inflammation caused by COVID and improve overall health. In five out of six inflammatory markers studied, Pentarlandir treatment groups showed either statistical signals of greater reductions in the inflammatory markers or a clear trend of greater reductions. Many secondary endpoints also showed encouraging trends.

In particular, the Pentarlandir treatment groups exhibited greater improvement in overall health status. In terms of clinical symptoms, Pentarlandir groups were associated with a greater reduction in total COVID-19 symptoms in the longer run (between two to eight weeks after randomization) than the placebo group. On average, Pentarlandir groups were associated with fewer days of worsening symptoms in half of the 24 COVID symptoms measured.

Pentarlandir was very well tolerated in both high- and low-dose groups with no serious adverse event. There were a limited number of adverse events overall (15%), most of which were mild in intensity. Only a few cases (4%) were related to the treatment drug. Higher dose treatment did not elicit more treatment-related adverse events. There were no cases of hospitalization, death, or discontinuation of the study due to adverse events.

SyneuRx is expected to launch the phase 3 study in the coming months. An optimal dose will be selected and the scope will expand to evaluate Pentarlandir's broad-spectrum antiviral activity in inhibiting SARS-CoV-2 as well as influenza viruses, including rigorous safety assessments, to be ready for the potential coinciding surges of flu and COVID-19.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT